Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Gastroenteropancreatic neuroendocrine tumor
Mouse model
Neuroendocrine carcinoma
Patient-derived xenograft
Therapy
Journal
Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
04
2020
accepted:
23
06
2020
pubmed:
3
7
2020
medline:
28
10
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a rare, heterogeneous group of tumors that originate from the endocrine system of the gastrointestinal tract and pancreas. GEP-NENs are subdivided according to their differentiation into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Since GEP-NENs represent rare diseases, only limited data from large prospective, randomized clinical trials are available, and recommendations for treatment of GEP-NEN are in part based on data from retrospective analyses or case series. In this context, tractable disease models that reflect the situation in humans and that allow to recapitulate the different clinical aspects and disease stages of GEP-NET or GEP-NEC are urgently needed. In this review, we highlight available data on mouse models for GEP-NEN. We discuss how these models reflect tumor biology of human disease and whether these models could serve as a tool for understanding the pathogenesis of GEP-NEN and for disease modeling and pharmacosensitivity assays, facilitating prediction of treatment response in patients. In addition, open issues applicable for future developments will be discussed.
Identifiants
pubmed: 32615560
pii: 000509864
doi: 10.1159/000509864
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-236Informations de copyright
© 2020 The Author(s). Published by S. Karger AG, Basel.